All In Biotech

Drug Trial Radar · NCT04669028

A Phase 3 Study of NE3107 in Probable Alzheimer's Disease

A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Probable Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 439 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

439

Actual

Start

Aug 5, 2021

Primary completion

Sep 30, 2023

Study completion Oct 25, 2023

Sponsor

Lead sponsor
BioVie Inc.Industry
Sponsor type
Industry
First posted
Dec 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

U.S. multicenter, parallel group study designed to evaluate the safety and efficacy of oral 20 mg twice daily (BID) NE3107 vs placebo in 400 adult subjects with mild to moderate probable AD. Dual co-primary endpoints (Clinical Dementia Rating Scale Sum of Boxes, CDR-SB and ADAS-Cog12) will be evaluated as the change from Baseline to Week 30. Secondary endpoints include measures of cognition, neuropsychological deficits, functional performance, and glycemic control. A subset of patients may volunteer for exploratory magnetic resonance imaging (volumetric changes) and positron emission tomography (cortical glucose metabolic rate) scans at baseline and week 30.

Conditions

  • Alzheimer Disease

Interventions

  • NE3107Drug

    NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.

  • PlaceboDrug

    capsules that do not contain NE3107

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)Time frame: baseline and week 30 (end of study)
  2. Change in Alzheimer's Disease Assessment Scale Cognitive Subscale 12 [ADAS Cog12]Time frame: baseline and week 30 (end of study)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Ohio State University

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.